Lugano, Switzerland - 15 June 2018 - Groundbreaking research will be revealed at this year's ESMO World Congress on Gastrointestinal Cancer (20-23 June, Barcelona, Spain), (1) celebrating 20 years of clinical progress in a group of diseases that affect both men and women worldwide.
Hepatocellular carcinoma, gastric cancer, colorectal cancer will be under the spotlight with results from the latest research in the field, ranging from chemotherapy through immunotherapy.
The Congress will bring together more than 3,500 professionals from across the globe willing to share pioneering research, innovative approaches, best practices and clinical insights in treating patients with cancers of the gastrointestinal tract: gastroenterologists, oncologists, pathologists, surgeons, clinical researchers, as well as patient advocates.
According to Congress Chair Eric Van Cutsem, "The research that will be presented at the ESMO 20th World Congress on Gastrointestinal Cancer proves to be some of the most impressive yet. I am confident that the exceptional programme will meet the high expectations of delegates coming from all over the world interested in learning the latest findings, engaging in productive exchange, and, most importantly, being guided by experts who can translate research into recommendations for daily patient care."
Sessions in the programme (2) are devoted to, among others, gastric and esophageal cancers, prevention and screening of colon cancer, cancer of the pancreas, diseases and cancers of the liver.
"We are very pleased to be marking a milestone in bringing together specialists from around the world to learn about exciting advancements, new treatment options and clinical best practices in gastrointestinal malignancies, said Congress Vice-Chair Josep Tabernero, ESMO President. "The meeting is truly a global platform from which we have an opportunity to build on 20 years of progress and propel better cancer care forward."
Research from the ESMO 20th World Congress on Gastrointestinal Cancer will be published in a supplement of Annals of Oncology.
- All abstracts will be made available online on Tuesday, 20 June 2018 at 8:00 CEST.
- Abstracts selected by the Scientific Committee for presentation as part of the agenda for the ESMO 20th World Congress on Gastrointestinal Cancer (designated with an O or LB before their number) are embargoed until the end of the scientific session during which they are presented.
Journalists are required to observe embargoes as indicated, thank you!
Press representatives are invited to attend an opening press conference for the ESMO 20th World Congress on Gastrointestinal Cancer. Congress Chairs will discuss highlights of the 2018 scientific programme that will spotlight promising research on key topics ranging from chemotherapy to immunotherapy in the areas of hepatocellular carcinoma, gastric cancer, colorectal cancer, and pancreatic cancer.
- When: 20 June 2018 - 10:00 CEST
- Where: Room 123 - Level 1 - CCIB - Centre de Convencions Internacional de Barcelona - Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain
- Who: Mario Dicato, MD, Congress Chair, Luxembourg Medical Center, Luxembourg - Eric Van Cutsem, MD, PhD, Congress Chair, University Hospital Gasthuisberg, Leuven, Belgium - Josep Tabernero, MD, PhD, Congress Vice Chair, ESMO President, Vall d'Hebron University Hospital, Barcelona, Spain
A Press badge will be granted to journalists employed by recognised news organizations for the purpose of editorial coverage. Representatives from qualified media outlets must represent editorial staff, not the advertising or marketing staff.
Members of the press can register at this link (3). Registered media are not eligible for continuing education credit.
ESMO Press Office - firstname.lastname@example.org
1- Congress webpage: http://esmo.
2- Scientific programme: http://www.
3- Media registration form: http://www.
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO World Congress on Gastrointestinal Cancer
Official hashtag: #WCGI2018
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
ESMO's educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide. Visit http://www.